Motley Fool Asset Management LLC Buys 684 Shares of DexCom, Inc. (NASDAQ:DXCM)

Motley Fool Asset Management LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 6.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 10,647 shares of the medical device company’s stock after buying an additional 684 shares during the period. Motley Fool Asset Management LLC’s holdings in DexCom were worth $1,321,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of DXCM. Valley National Advisers Inc. boosted its stake in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. MV Capital Management Inc. boosted its position in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after buying an additional 138 shares in the last quarter. Washington Trust Advisors Inc. grew its stake in DexCom by 120.6% during the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after buying an additional 193 shares during the last quarter. NBC Securities Inc. bought a new stake in DexCom during the third quarter worth about $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new stake in shares of DexCom during the third quarter worth approximately $48,000. 97.75% of the stock is currently owned by institutional investors.

Insider Buying and Selling at DexCom

In related news, CFO Jereme M. Sylvain sold 3,363 shares of the firm’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Jereme M. Sylvain sold 3,363 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now directly owns 71,142 shares of the company’s stock, valued at approximately $8,304,405.66. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the transaction, the chief executive officer now directly owns 333,526 shares in the company, valued at approximately $44,479,027.36. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,375 shares of company stock valued at $25,530,859. Corporate insiders own 0.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on DXCM shares. UBS Group increased their price target on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Tuesday. Raymond James lifted their price target on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a report on Friday. Royal Bank of Canada initiated coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an “outperform” rating and a $165.00 price target on the stock. Finally, Citigroup raised their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $141.67.

DexCom Trading Down 9.9 %

Shares of DexCom stock traded down $13.67 on Friday, hitting $124.34. 8,576,828 shares of the company’s stock traded hands, compared to its average volume of 3,047,021. The firm’s 50-day moving average price is $130.98 and its two-hundred day moving average price is $118.02. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. The stock has a market capitalization of $49.24 billion, a PE ratio of 97.41, a price-to-earnings-growth ratio of 2.37 and a beta of 1.20. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The business had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. On average, research analysts expect that DexCom, Inc. will post 1.76 EPS for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.